NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CytomX Therapeutics, Inc. (CTMX) Stock Analysis

CytomX Therapeutics, Inc. (CTMX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CTMX

$3.71

+$0.03 (+0.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTMX with… →

CTMX Key Statistics

As of Sep 4, 2026
Trading
Open
$3.64
Previous Close
$3.68
Day's Range
3.53–3.73
52-Week Range
1.90–8.21
Volume
2.30M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.14
Valuation
Market Cap
$808.41M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
44.17
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.57
Financials (FY)
Revenue (FY)
$76.20M−44.82%
Net Income (FY)
−$17.37M−154.50%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
217.90M
1-Year Return
+76.67%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.98M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTMX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.91%
2025+313.59%
2024−33.55%
2023−3.13%
2022−63.05%
2021−33.89%
2020−21.18%
2019−44.97%
2018−28.47%
2017+92.08%
2016 (partial year)−2.22%

As of September 4, 2026.

CTMX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$76.20M−$17.37M−22.8%
2024$138.10M$31.87M23.1%
2023$101.21M−$569.00K−0.6%
2022$53.16M−$99.32M−186.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$76.20M—−$22.36M−$17.37M−22.8%
2024$138.10M—$25.00M$31.87M23.1%
2023$101.21M—−$6.48M−$569.00K−0.6%
2022$53.16M—−$101.34M−$99.32M−186.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CTMX Valuation vs Biotechnology Median

Median of 656 stocks
MetricCTMXBiotechnology medianvs median
P/S ratio44.1715.26189% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values CytomX Therapeutics, Inc. (CTMX) at $808.41M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 69 employees.

The 52-week range on file runs from $1.90 to $8.21. CTMX last closed at $3.71 on September 4, 2026. That is +$0.03 (+0.82%) against the previous close. The latest close sits 95.26% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $76.20M. Against the prior fiscal year total of $138.10M, that is a change of −44.82%. The same year closed with a net loss of $17.37M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.57.

Across the 4 fiscal years on file, revenue moves from $53.16M in 2022 to $76.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 44.17. On price-to-sales that is 189.37% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +76.67%. Measured over 10 years, that is −11.13% a year compounded. Beta against the wider market is reported at 2.14. Annualized volatility over the trailing 10 years is 111.4%.

Growth & Income

The record shows no dividend for CTMX.

Across the complete calendar years on file, 2025 returned +313.59% and 2022 returned −63.05%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −12.91% year to date.

Peer Comparison

CytomX Therapeutics, Inc. (CTMX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CytomX Therapeutics, Inc. CTMX $808.41M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CytomX Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Visit website →